Dr. Frey on the Utility of CART22-65s with huCART19 in Relapsed/Refractory ALL

Noelle V. Frey, MD, MSCE, Constance and Sankey Williams Associate Professor, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, discusses the results of a study evaluating the utility of co-administered CART22-65s and huCART19 in relapsed/refractory acute lymphoblastic leukemia (ALL) that were presented at the 2021 ASH Annual Meeting & Exposition.

Regarding safety, the results of the phase 1 study showed that 2 of the 13 patients infused with CART22-65s and huCART19 developed toxicity before the 28-day assessment. Of these patients, 1 died from therapy-related complications, and 1 developed rapidly progressive disease, Frey said. However, the 11 patients who were evaluable at the 1-month time point allachieved complete remissions that were minimal residual disease negative, Frey explains.

Overall, the co-administered products were well tolerated; cytokine release syndrome (CRS) and neurotoxicity were observed but manageable, Frey said. Hemophagocytic lymphohistiocytosis-like syndrome (HLH) was a unique toxicity attributed to CART22-65s. HLH is clinically distinct from traditional CRS and has been noted in CART22-65s products before, Frey adds. The toxicity was mitigated in the patient who developed HLH, and they were able to continue with a sustained remission, Frey concludes.